Pms88 - Real World Persistence and Adherence With Oral Bisphosphonates for Osteoporosis - A Systematic Review

Abstract

disagree and 7¼completely agree). Consensus was established when at least 75% of the respondents reached agreement (5-7 points) or disagreement (1-3 points). Descriptive statistics were applied. RESULTS: One hundred and fifteen panelists completed the questionnaire (rheumatologists: 75.7%; dermatologists: 15.7%; nurses 1.7%; hospital pharmacists: 2.6%; clinical psychologists: 1.7%; and healthcare managers: 2.6%). In PsA patients with peripheral involvement, consensus was reached on the use of either Disease Activity in Psoriatic Arthritis (DAPSA) + Psoriatic Arthritis Impact of Disease (PsAID-12) (S: 91.2%, F: 85.2% agreement) or Minimal Disease Activity (MDA) + PsAID-12 + C-reactive protein (S: 90.5%, F: 76.5%). In PsA patients with axial involvement, consensus was reached on the use of Ankylosing Spondylitis Disease Activity Score (ASDAS) + PsAID-12 (S: 85.3%, F: 76.5%). CONCLUSIONS: A multidisciplinary consensus has been reached on the most suitable and feasible sets of measurement instruments, including clinical and PRO measures, to assess the effectiveness of BT in PsA patients in the Spanish setting. Further research should explore a therapeutic success definition.

The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study

“…Bisphosphonates were shown to effectively reduce periprosthetic bone resorption and improve the longterm duration of knee prosthesis [7]. Guidance from the UK National Institute for Health and Care Excellence (NICE) recommends alendronate as the first choice of OP treatment [8], and oral administration is the most commonly used way for using bisphosphonates to treat osteoporosis [9]. It has been reported that oral alendronate not only prevented osteoclast-mediated bone loss and associated implant loosening in total hip arthroplasty (THA) [10], but also significantly reduced early postoperative periprosthetic bone loss in TKA patients [11].…”